Due to the increased nocturnal systolic BPV and inflammatory factors induced by insomnia in ESRD patients, we will adopt outcome measurements including 24-Hour ambulatory blood pressure and blood sample (plasma levels of C-reactive protein (CRP) and D-Dimer) to objectively investigate the effect of EA for insomnia in ESRD undergoing MHD. This evidence concerns the gene CRP and insomnia.